Skip to content

News

2nd December 2025

Aera Therapeutics to Present Preclinical Data on AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases, at the 67th American Society of Hematology (ASH) Annual Meeting

Read More
5th November 2025

Aera Therapeutics Announces Participation in Upcoming Investor Conferences

Read More
24th September 2025

Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development Candidate, AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases

Read More
2nd September 2025

Aera Therapeutics Appoints Bill Querbes, Ph.D., as Chief Scientific Officer

Read More
12th May 2025

Aera Therapeutics Appoints Paul Conrad, Ph.D., MBA, as Chief Business and Financial Officer

Read More
16th February 2023

Aera Therapeutics Launches with $193 Million in Financing to Enable and Advance the Next Generation of Transformative Genetic Medicines

Read More
Top